Recursion Pharmaceuticals
RXRX
$3.52
+5.39%
Recursion Pharmaceuticals is a clinical-stage biotechnology company that aims to industrialize drug discovery by integrating automation, data science, and engineering to decode biology and identify new therapeutics. The company positions itself as a technology-driven disruptor in the biotech space, leveraging its proprietary platform to rapidly screen and validate drug candidates across a wide range of diseases. The current investor narrative is intensely focused on the company's ability to translate its ambitious technological platform into tangible clinical and financial results, with recent attention highlighting its status as a highly speculative, 'beaten-down' growth stock that remains a conviction holding for certain high-profile investors despite significant volatility and ongoing losses.…
RXRX
Recursion Pharmaceuticals
$3.52
Related headlines
Investment Opinion: Should I buy RXRX Today?
Rating: Hold. The core thesis is that while Recursion's platform ambition is compelling, its catastrophic financials, extreme valuation, and binary risk profile make it unsuitable for most investors outside of a highly speculative, high-conviction portfolio allocation.
Supporting evidence for this Hold rating includes the stock's deeply oversold technical state (trading 9.8% above its 52-week low), its strong balance sheet (debt/equity of 0.07), and backing from thematic investors. However, these are overwhelmingly countered by severe negatives: a P/S of 24.50x, an EPS of -$0.35, a net margin of -863.35%, and a negative ROE of -57.01%. The lack of analyst consensus (only 2 covering) and wide revenue estimate range further underscore the extreme uncertainty.
The thesis would upgrade to a speculative Buy only if the stock breaks below $2.75 on no new negative news, offering a deeper margin of safety, or if the company announces a major platform partnership or positive clinical data that validates its technology. It would downgrade to a Sell if the company announces a dilutive equity offering, reports revenue below the low estimate of $115M, or if the stock breaks key support at $2.77 on high volume. Based on the available data, the stock is overvalued on any fundamental metric but may be fairly valued or even undervalued relative to its own speculative potential, a distinction that hinges entirely on future binary outcomes.
Sign up to view all
RXRX 12-Month Price Forecast
The assessment is neutral with medium confidence. The stock is a classic binary option: its technology platform could be revolutionary, but its financials are disastrous. The current price reflects significant skepticism, offering a speculative entry point, but the path to value realization is long, risky, and dependent on unproven clinical and commercial outcomes. The stance would upgrade to bullish only upon concrete validation of the platform (e.g., a major partnership or clinical success) and would downgrade to bearish on any indication of financing distress or a material failure in its R&D pipeline.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Recursion Pharmaceuticals's 12-month outlook, with a consensus price target around $4.58 and implied upside of +30.1% versus the current price.
Average Target
$4.58
2 analysts
Implied Upside
+30.1%
vs. current price
Analyst Count
2
covering this stock
Price Range
$3 - $5
Analyst target range
Analyst coverage for RXRX is extremely limited, with only 2 analysts providing estimates, indicating this is a stock with minimal institutional research coverage which can lead to higher volatility and less efficient price discovery. The provided data includes revenue and EPS estimates but does not contain a consensus price target, Buy/Hold/Sell distribution, or a target price range, making it impossible to calculate implied upside or downside or to gauge the bullish or bearish sentiment among the few covering firms. The wide range of revenue estimates, from a low of $115.1 million to a high of $455.2 million, signals exceptionally high uncertainty and low conviction regarding the company's near-term commercial prospects, which is typical for a clinical-stage biotech but a major risk factor for investors.
Bulls vs Bears: RXRX Investment Factors
The evidence currently favors the bear case due to the company's severe fundamental weaknesses—catastrophic profitability, unsustainable cash burn, and an exorbitant sales-based valuation with no earnings support. The bull case rests almost entirely on speculative future platform success and the stock's deeply oversold technical condition. The single most important tension in the investment debate is whether Recursion's technology platform can successfully transition from a cash-burning R&D operation to a validated, revenue-generating drug discovery engine before its financial runway expires. The resolution of this binary outcome will determine if the current price is a bargain or a value trap.
Bullish
- Strong balance sheet with minimal debt: The company's debt-to-equity ratio is a very low 0.07, indicating negligible financial leverage risk. Furthermore, a current ratio of 5.5 provides ample short-term liquidity to fund operations without immediate solvency concerns.
- Deeply oversold technical condition: The stock is trading at $3.15, near the bottom of its 52-week range ($2.77 to $7.18), representing a 41.67% decline over the past year. This extreme sell-off, coupled with a relative strength of -64.35 vs. the SPY, suggests negative sentiment may be overdone, creating a potential value entry point.
- High-conviction backing from thematic investors: Recent news highlights that high-profile investors like Cathie Wood of ARK Invest are actively buying 'beaten-down' growth stocks like RXRX. This provides a source of institutional support and validates the long-term platform thesis despite near-term volatility.
- Platform potential priced at a discount: The stock's EV/Sales of 15.49x, while high, is lower than its trailing P/S of 24.50x, suggesting some valuation compression has already occurred. For a company aiming to industrialize drug discovery, this may represent a discounted entry relative to its own historical valuation.
Bearish
- Severe and persistent unprofitability: The company is deeply unprofitable with a trailing EPS of -$0.35, a net margin of -863.35%, and a gross margin of -61.96%. This indicates it costs significantly more to generate revenue than it brings in, a critical flaw that necessitates continuous external financing.
- Extremely high valuation on sales: With a Price-to-Sales ratio of 24.50x and an EV/Sales of 15.49x, the stock trades at a massive premium to current revenue. This valuation is entirely dependent on future platform success, leaving no margin of safety if execution falters.
- Catastrophic cash burn and negative returns: The company exhibits a negative price-to-cash-flow ratio of -4.92 and a Return on Equity of -57.01%, confirming it is burning substantial cash and destroying shareholder value. This unsustainable model heightens the risk of future dilutive equity offerings.
- Extreme uncertainty and low analyst coverage: Only 2 analysts cover the stock, and their revenue estimates range wildly from $115.1M to $455.2M. This lack of coverage and consensus signals exceptionally high uncertainty and low conviction in the company's near-term commercial prospects.
RXRX Technical Analysis
The stock is in a pronounced and sustained downtrend, evidenced by a 1-year price decline of 41.67% and a 6-month decline of 27.25%. With a current price of $3.15, it is trading near the bottom of its 52-week range, at approximately 9.8% of the range from the $2.77 low to the $7.18 high, indicating the stock is deeply oversold and may represent a value opportunity, though it also signals persistent negative momentum and fundamental concerns. Recent momentum shows a stark divergence, with the 1-month price change at 0.0% and the 3-month change at -7.89%, suggesting the severe downtrend may be entering a phase of consolidation or basing, as short-term selling pressure has abated even as the longer-term trend remains negative; this is further supported by a relative strength reading of -64.35 over one year versus the SPY. Key technical levels are clearly defined, with immediate support at the 52-week low of $2.77 and major resistance at the 52-week high of $7.18; a breakdown below $2.77 would signal a new leg down and likely trigger further selling, while a sustained move above the recent consolidation range would be needed to suggest a reversal. The stock's beta of 1.004 indicates its volatility is essentially in line with the broader market, which is notable given its steep decline, suggesting its moves are driven more by company-specific factors than systemic risk.
Beta
1.00
1.00x market volatility
Max Drawdown
-58.2%
Largest decline past year
52-Week Range
$3-$7
Price range past year
Annual Return
-34.8%
Cumulative gain past year
| Period | RXRX Return | S&P 500 |
|---|---|---|
| 1m | +11.0% | -3.6% |
| 3m | +19.7% | +15.3% |
| 6m | -17.2% | +6.1% |
| 1y | -34.8% | +18.6% |
| ytd | -16.2% | +6.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RXRX Fundamental Analysis
Revenue trajectory and growth cannot be analyzed from the provided data, as quarterly financials, income statements, and revenue segments are not available; analyst estimates suggest expected revenue of $247.5 million, but without historical figures, assessing growth acceleration or deceleration is impossible, which itself is a critical data gap for a clinical-stage company. The company is deeply unprofitable, with a trailing EPS of -$0.35, a net margin of -863.35%, and a gross margin of -61.96%, indicating it costs the company significantly more to generate its revenue than the revenue itself brings in, a common but severe situation for pre-revenue biotechs burning cash on R&D. The balance sheet and cash flow health are mixed, with a strong current ratio of 5.5 indicating ample short-term liquidity, and a very low debt-to-equity ratio of 0.07 suggesting minimal financial leverage risk; however, the negative price-to-cash-flow ratio of -4.92 and deeply negative ROE of -57.01% confirm the company is burning substantial cash to fund operations and is far from generating returns for equity holders, leaving it dependent on external financing to sustain its drug development pipeline.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RXRX Overvalued?
Given the company's negative net income and negative EBITDA, the most appropriate primary valuation metric is EV/Sales, which stands at 15.49x. The trailing Price-to-Sales ratio is also extremely high at 24.50x, reflecting the market's assignment of value to the company's platform and pipeline potential rather than current earnings, with the forward PE being negative at -3.58x, underscoring that profitability is not expected in the near term. Peer comparison data for the biotechnology industry is not provided in the valuation dataset, so a quantitative assessment of whether the 15.49x EV/Sales represents a premium or discount cannot be made; this lack of comparative context is a significant analytical hurdle. Historical context for the stock's own valuation multiples is also unavailable, as historical ratios data is missing, preventing an analysis of whether the current EV/Sales is at the high or low end of its own historical range, which would help gauge if the market's optimism or pessimism is extreme.
PE
-2.8x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-2.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on the company's unsustainable business model. With a gross margin of -61.96% and a net margin of -863.35%, the company loses over $8 for every $1 of revenue it generates. This is compounded by a negative ROE of -57.01% and negative cash flow, indicating it is rapidly consuming capital to fund operations with no near-term path to self-sufficiency. The balance sheet, while currently liquid with a 5.5 current ratio, will require further dilutive financing if profitability is not achieved, posing a direct risk to existing shareholders.
Market & Competitive Risks are elevated due to valuation compression and sector sentiment. The stock's EV/Sales of 15.49x represents a high multiple that is vulnerable to derating if growth narratives fall out of favor or if clinical setbacks occur. With a beta of 1.004, its volatility aligns with the market, but its 41.67% annual decline against a 22.68% SPY gain shows it is suffering from severe company-specific de-risking. The recent news framing it as a 'highly speculative' holding for bargain hunters underscores its perception as a binary, high-risk asset rather than a fundamental growth story.
Worst-Case Scenario involves a failure to achieve clinical or platform milestones, leading to a loss of investor confidence and an inability to raise capital on favorable terms. This could trigger a downward spiral where cash burn necessitates a highly dilutive equity offering at a severely depressed price, further eroding shareholder value. The realistic downside from the current price of $3.15 is a retest and break below the 52-week low of $2.77, representing a -12% decline. A more severe bear case, reflecting a total loss of the platform premium, could see the stock fall 50-60% from current levels, mirroring its historical max drawdown of -58.17%.
FAQ
The key risks are, in order of severity: 1) Financial Sustainability Risk: The company is burning cash with a gross margin of -61.96% and negative ROE of -57.01%, risking the need for dilutive financing. 2) Platform Validation Risk: The entire investment thesis hinges on the unproven Recursion OS platform successfully discovering and developing drugs; clinical failure would collapse the narrative. 3) Valuation Risk: The P/S of 24.50x leaves the stock vulnerable to severe multiple compression if growth expectations are not met. 4) Liquidity & Sentiment Risk: With only 2 analyst covers and a short ratio of 9.9, the stock is prone to high volatility and sentiment-driven swings disconnected from fundamentals.
The 12-month forecast for RXRX is a wide range of outcomes due to its binary nature. The base case (50% probability) sees the stock trading between $3.00 and $4.50 as it continues to report losses without a definitive catalyst. The bull case (20% probability) targets $5.50 to $7.18 (its 52-week high) on positive clinical or partnership news. The bear case (30% probability) warns of a drop to $2.00-$2.77 (its 52-week low) on a clinical setback or poor financial results. The most likely scenario is the base case of continued volatile, range-bound trading, as the company lacks the near-term catalysts needed to resolve the high uncertainty surrounding its platform.
RXRX is dramatically overvalued on all standard fundamental metrics due to its lack of profits and negative cash flow. Its Price-to-Sales ratio of 24.50x and EV/Sales of 15.49x are extremely high, indicating the market is pricing in massive future growth from its platform. Without peer or historical comparison data, it's impossible to say if this premium is justified relative to other platform biotechs. The valuation implies the market expects Recursion to successfully translate its technology into a high-margin, scalable drug discovery engine. Therefore, it is not undervalued on fundamentals but could be considered undervalued relative to its own speculative potential if an investor has high conviction in that future outcome.
RXRX is not a 'good' stock to buy for most traditional investors seeking stability, income, or near-term fundamentals. It is a highly speculative investment suitable only for those with a high risk tolerance who are making a conviction bet on its unproven technology platform. The stock is down 41.67% in the past year and trades near its 52-week low, which may appeal to bargain hunters, but its catastrophic profitability (net margin -863.35%) and high valuation (P/S 24.50x) present extreme downside risk. It could be a good buy for a very specific investor profile: a long-term, thematic investor willing to accept total loss potential for the chance of a multi-bagger return if the platform succeeds.
RXRX is unsuitable for short-term trading for all but the most sophisticated traders due to its high volatility, low liquidity, and sensitivity to binary news. Its beta of 1.004 suggests market-correlated moves, but company-specific news drives extreme swings. For investment, it is only suitable for a very long-term horizon (5+ years), as validating its platform and achieving profitability will take many years. There is no dividend, and earnings are deeply negative, eliminating any income or short-term fundamental support. An investor must be prepared to hold through significant volatility and potential dilution while waiting for the long-term thesis to play out, making it a purely long-term, speculative holding.